Movano health advances to final phase of fda review process for eviemed ring

Following the positive outcome of a recent agency meeting, the company will continue to work closely with the fda to bring this pioneering healthcare product to market pleasanton, calif. , sept. 3, 2024 /prnewswire/ --  movano health  (nasdaq: move) announced today that a productive in-person meeting with the fda on august 15, 2024, resulted in a positive outcome regarding the eviemed ring's wellness features and metrics.
MOVE Ratings Summary
MOVE Quant Ranking